Minor association of kinase insert domain-containing receptor gene polymorphism (rs2071559) with myocardial infarction in Caucasians with type 2 diabetes mellitus: Case-control cross-sectional study

Clinical Biochemistry

Volumn 47, Issue 16-17, 2014, Pages 192-196

  Kariž, Stojan ^a   Petrovič, Daniel ^b  

^a General Hospital Izola   (Slovenia)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cross sectional study; Genetic polymorphisms; Genetic risk factors; Myocardial infarction; Receptor KDR; Rs2071559; Rs2305948; Type 2 diabetes; Vascular endothelial growth factor

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MYOCARDIAL INFARCTION;

AGED; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84908612143     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.08.004     Document Type: Article

References (42)

1. Guariguata L., Whiting D.R., Hambleton I., Beagley J., Linnenkamp U., Shaw J.E. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014, 103(2):137-149.
2. Moreno P.R., Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004, 44(12):2293-2300.
3. Grundy S.M., Benjamin I.J., Burke G.L., Chait A., Eckel R.H., Howard B.V., et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999, 100(10):1134-1146.
4. Khurana R., Simons M., Martin J.F., Zachary I.C. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005, 112(12):1813-1824.
5. Moreno P.R., Purushothaman K.R., Fuster V., Echeverri D., Truszczynska H., Sharma S.K., et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004, 110(14):2032-2038.
6. Hayden M.R., Tyagi S.C. Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation. Cardiovasc Diabetol 2004, 3:1.
7. Olson F.J., Strömberg S., Hjelmgren O., Kjelldahl J., Fagerberg B., Bergström G.M. Increased vascularization of shoulder regions of carotid atherosclerotic plaques from patients with diabetes. J Vasc Surg 2011, 54(5):1324-1331.
8. Pelisek J., Well G., Reeps C., Rudelius M., Kuehnl A., Culmes M., et al. Neovascularization and angiogenic factors in advanced human carotid artery stenosis. Circ J 2012, 76(5):1274-1282.
9. Inoue M., Itoh H., Ueda M., Naruko T., Kojima A., Komatsu R., et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation 1998, 98(20):2108-2116.
10. Rahimi N. Vascular endothelial growth factor receptors: molecular mechanisms of activation and therapeutic potentials. Exp Eye Res 2006, 83(5):1005-1016.
11. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269(43):26988-26995.
12. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 39-kinase/Akt signal transduction pathway. J Biol Chem 1998, 273(46):30336-30343.
13. Wang Y., Zheng Y., Zhang W., Yu H., Lou K., Zhang Y., et al. Polymorphisms of KDR gene are associated with coronary heart disease. J Am Coll Cardiol 2007, 50(8):760-767.
14. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001, 7(4):425-429.
15. Hauer A.D., van Puijvelde G.H., Peterse N., de Vos P., van Weel V., van Wanrooij E.J., et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(9):2050-2057.
16. Petrovan R.J., Kaplan C.D., Reisfeld R.A., Curtiss L.K. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007, 27(5):1095-1100.
17. Morsi W.G., Shaker O.G., Ismail E.F., Ahmed H.H., El-Serafi T.I., Maklady F.A., et al. HO-1 and VEGF gene expression in human arteries with advanced atherosclerosis. Clin Biochem 2006, 39(11):1057-1062.
18. Heeschen C., Dimmeler S., Hamm C.W., Boersma E., Zeiher A.M., Simoons M.L. CAPTURE (c7E3 Anti-Platelet Therapy in Unstable REfractory angina) Investigators. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 2003, 107(4):524-530.
19. Hao Q., Wang L., Tang H. Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells. Am J Physiol Cell Physiol 2009, 296(4):C821-C827.
20. Pantsulaia I., Trofimov S., Kobyliansky E., Livshits G. Heritability of circulating growth factors involved in the angiogenesis in healthy human population. Cytokine 2004, 27(6):152-158.
21. Howell W.M., Ali S., Rose-Zerilli M.J., Ye S. VEGF polymorphisms and severity of atherosclerosis. J Med Genet 2005, 42(6):485-490.
22. Zhang W., Sun K., Zhen Y., Wang D., Wang Y., Chen J., et al. VEGF receptor-2 variants are associated with susceptibility to stroke and recurrence. Stroke 2009, 40(8):2720-2726.
23. Abhary S., Burdon K.P., Gupta A., Lake S., Selva D., Petrovsky N., et al. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci 2009, 50(12):5552-5558.
24. Yang X., Deng Y., Gu H., Ren X., Li N., Lim A., et al. Candidate gene association study for diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis 2014, 20:200-214.
25. Petrovic D., Verhovec R., Globocnik Petrovic M., Osredkar J., Peterlin B. Association of vascular endothelial growth factor gene polymorphism with myocardial infarction in patients with type 2 diabetes. Cardiology 2007, 107(4):291-295.
26. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26(Suppl. 1):S5-S20.
27. Alpert J.S., Thygesen K., Antman E., Bassand J.P. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000, 36(3):959-969.
28. Andraweera P.H., Dekker G.A., Thompson S.D., North R.A., McCowan L.M., Roberts C.T. The interaction between the maternal BMI and angiogenic gene polymorphisms associates with the risk of spontaneous preterm birth. Mol Hum Reprod 2012, 18(9):459-465.
29. Orasanu G., Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol 2009, 53(5 Suppl.):S35-S42.
30. Ferrara N., Gerber H.P. The role of vascular endothelial growth factor in angiogenesis. Acta Haematol 2001, 106(4):148-156.
31. Rask-Madsen C., King G.L. Differential regulation of VEGF signaling by PKC-alpha and PKC-epsilon in endothelial cells. Arterioscler Thromb Vasc Biol 2008, 28(5):919-924.
32. Shiojima I., Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res 2002, 90(12):1243-1250.
33. Ling L., Shen Y., Wang K., Jiang C., Fang C., Ferro A., et al. Worse clinical outcomes in acute myocardial infarction patients with type 2 diabetes mellitus: relevance to impaired endothelial progenitor cells mobilization. PLoS One 2012, 7(11):e50739.
34. Kuzuya M., Ramos M.A., Kanda S., Koike T., Asai T., Maeda K., et al. VEGF protects against oxidized LDL toxicity to endothelial cells by an intracellular glutathione-dependent mechanism through the KDR receptor. Arterioscler Thromb Vasc Biol 2001, 21(5):765-770.
35. Kota S.K., Meher L.K., Jammula S., Kota S.K., Krishna S.V., Modi K.D. Aberrant angiogenesis: the gateway to diabetic complications. Indian J Endocrinol Metab 2012, 16(6):918-930.
36. Chou E., Suzuma I., Way K.J., Opland D., Clermont A.C., Naruse K., et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002, 105(3):373-379.
37. Sasso F.C., Torella D., Carbonara O., Ellison G.M., Torella M., Scardone M., et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 2005, 46(5):827-834.
38. Simons M. Angiogenesis, arteriogenesis, and diabetes. Paradigm reassessed?. J Am Coll Cardiol 2005, 46(5):835-837.
39. Adamis A.P., Aiello L.P., D'Amato R.A. Angiogenesis and ophthalmic disease. Angiogenesis 1999, 3(1):9-14.
40. Tepper O.M., Galiano R.D., Capla J.M., Kalka C., Gagne P.J., Jacobowitz G.R., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106(22):2781-2786.
41. Awata T., Inoue K., Kurihara S., Ohkubo T., Watanabe M., Inukai K., et al. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002, 51:1635-1639.
42. Duh E., Aiello L.P. Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox. Diabetes 1999, 48:1899-1906.